Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss per share

Loss per share

3 Months Ended

Mar. 31, 2024

Note 4 — (Loss)/profit per share

The following tables reconcile the numerator and denominator in the basic and diluted (loss)/profit per share computation (in thousands):


	Three months ended
	March 31,
	2024		2023
Numerator for basic and diluted (loss)/profit per share
Net (loss)/profit attributable to ordinary shareholders	$	(48,503)	$	1,036
Net (loss)/profit attributable to ordinary shareholders used for basic and diluted (loss)/profit per share	$	(48,503)	$	1,036


	Three months ended
	March 31,
	2024	2023
Denominator for basic (loss)/profit per share - Weighted average shares outstanding	1,451,241,661	991,330,402
Effect of dilutive securities:
Employee stock options	—	8,946,213
Denominator for diluted (loss)/profit per share	1,451,241,661	1,000,276,615

The dilutive effect of 249,957,127 and 128,614,053 stock options outstanding as of March 31, 2024 and 2023 respectively have been excluded from the diluted (loss)/profit per share calculation for the three months ended March 31, 2024 and 2023 because they would have an antidilutive effect on the (loss)/profit per share for the period.